drugset / Trial / NCT06411821
Ulixertinib in People With Histiocytic Neoplasms
Phase 2
Recruiting
38 enrolled
Memorial Sloan Kettering Cancer Center
BioMed Valley Discoveries, Inc · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The researchers are doing this study is to find out whether ulixertinib is an effective and safe treatment for people with histiocytic neoplasms.
Timeline
- Start
- 2024-05-07
- Primary completion
- 2027-05
- Completion
- 2027-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ulixertinib | Small molecule | 300 mg | — |